Sep 17 2009
Antidepressant drug Paxil, which generated about 2.1% of GlaxoSmithKline's total revenue last year, has been known to cause birth defects, but the world's second-biggest drugmaker hid its risks to pump up profits, a Philadelphia court has heard.
According to available information, Glaxo failed to properly test the drug and urged scientists to conceal Paxil's risks. The Philadelphia trial is the first of more than 600 cases against the London-based company.
See:
-- GlaxoSmithKline News - http://pharmaceuticals.einnews.com/news/glaxosmithkline
-- Paxil News - http://pharmaceuticals.einnews.com/news/paxil
-- Latest Pharmaceutical News - http://pharmaceuticals.einnews.com/